Logo

HGS, Fifteen Years in Review

Dec 29, 2006

The Washington Post featured an article on Human Genome Sciences' epic battle to get a drug to market. The story follows a patient who receives an experimental drug for hepatitis in a time that, for HGS, represents "the clearing of its biggest hurdle to date: The Rockville company, now nearly 15 years old, has finally entered the last stage of testing for one of its drugs." (HGS expected to bring another drug, this one for lupus, to the same testing phase in a matter of days.)

The article also takes readers on a nostalgic stroll to the beginning of HGS, when founder William Haseltine seemed to investors and (some) pharmaceutical companies like a sure bet. Fifteen years later, those people are holding their breath and hoping that these drugs will turn out to be the wonder they've been awaiting.

 

Breaking News
The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.